What happened when people who felt tired tried 5-ALA?

In a Japanese study, 70 otherwise healthy adults who felt physically tired most days rated their fatigue on a 100-point scale. Researchers randomly assigned them to two groups. Both groups received the same amount of iron in their tablets. One group also received 5-aminolevulinic acid phosphate, usually shortened to 5-ALA. [1]

Over eight weeks, average fatigue scores fell from 73 to about 59 with added 5-ALA and from 66 to about 63 with iron alone. The change over time differed significantly between groups. The group receiving 5-ALA started out more tired, and the study ended after eight weeks. Although participants also reported less work-related fatigue, the groups showed no clear difference in work efficiency or tiredness on waking. [1]

Why do researchers pair 5-ALA with iron?

Your body makes 5-ALA as an early step in building heme. Iron sits at the centre of heme. In red blood cells, heme lets hemoglobin carry oxygen. In mitochondria, heme is part of proteins that help cells release energy from food. That biology explains the interest in pairing 5-ALA with an iron salt called sodium ferrous citrate. Whether someone feels better after taking it is a question a trial can test. [1] [2] [3]

Did exercise or muscle performance change?

Ten older women who already did interval walking tried the combination and a placebo for a week each, in different orders. They used less oxygen at the same cycling workload and spent more time walking briskly during the week on the combination. A separate crossover trial in 14 healthy volunteers found similar heart rates and blood lactate levels on cycling tests with and without the supplement, although some antioxidant measurements differed at the higher workload. Both experiments were small and brief. [4] [5]

A larger trial randomized 100 older adults with sarcopenia, a condition involving loss of muscle mass and function. Researchers compared four 5-ALA and iron formulations with an iron-containing control. After 12 weeks, the groups had similar changes in the main measure of muscle mass. Some grip strength comparisons favoured 5-ALA. In a separate experiment, male mice eating a high-fat diet preserved muscle mass and strength with the combination. The human trial gives a more direct answer about people who already have muscle loss. [6] [7]

What do the blood sugar results mean?

In a 12-week trial, 212 adults with mildly elevated blood sugar received one of three combinations of 5-ALA phosphate and iron or a placebo. Compared with placebo, the highest-dose group had a 2.3 mg/dL greater reduction in fasting glucose and a 14.2 mg/dL greater reduction two hours after a glucose drink. HbA1c, which reflects average blood sugar over several months, showed no appreciable change. [8]

One 24-week trial randomized 101 adults who were already taking metformin or a sulfonylurea for type 2 diabetes. They added either 5-ALA hydrochloride with sodium ferrous citrate or placebo. The sponsor posted results in the EU trial register. Among the 100 participants in the main analysis, the adjusted average HbA1c fell by 0.12 percentage points in both groups. [9]

Another sponsor-posted study enrolled 218 adults with type 2 diabetes. Participants taking a single oral diabetes medicine at enrollment went through a washout period before treatment. At 24 weeks, adjusted average HbA1c fell by 0.27 percentage points on the higher-dose combination, by 0.01 on the lower dose and by 0.00 on placebo. The register reports a statistically significant overall comparison across the three groups in 213 participants. These are results in people who already had diabetes. Whether the combination prevents diabetes is a separate, unanswered question. [15]

What about fatigue after COVID-19?

There is a trial that asked this question directly. A Tokyo team randomly assigned 42 people with fatigue after COVID-19 to the combination or a matching placebo for 28 days. Forty completed treatment. The main aim was to assess safety. The change in fatigue over four weeks did not differ significantly between groups. The study leaves the longer-term effects on persistent fatigue open. [11]

Researchers also studied the combination during the infection itself. A separate 50-person randomized, open-label trial in Japan found no significant difference in viral load or overall symptom scores over 14 days. At day 14, a larger proportion of the treatment group reported relief of some individual symptoms, including altered taste. When participants and investigators know which treatment was given, ratings of individual symptoms need careful interpretation. One participant developed severe appetite loss that prolonged hospitalization and improved after the dose was reduced. [10]

How does the Leigh syndrome trial fit in?

Leigh syndrome is a rare mitochondrial disease. A phase 3 trial used SPP-004, a formulation of 5-ALA hydrochloride and sodium ferrous citrate. Fifty-four people started treatment. After 24 weeks, 28 who met the improvement criteria entered a blinded phase and were assigned to continue SPP-004 or switch to a comparison treatment containing a smaller amount of iron and no 5-ALA. This design asks whether an initial improvement can be maintained among people who have already responded. [12]

By 48 weeks of the blinded phase, 2 of 13 people included in the SPP-004 efficacy analysis and 7 of 14 in the placebo group had stopped because the treatment effect was inadequate. The difference in those proportions, the main outcome, fell short of statistical significance. A secondary analysis found that people who stayed on SPP-004 went longer before stopping for that reason. Serious adverse events affected 9 of 14 people on SPP-004 and 1 of 14 on placebo. The investigators considered these events more likely related to the underlying disease. Those small groups leave the cause of the imbalance uncertain. [12]

In July 2026 the developer described SPP-004 as an unapproved formulation under development. A different 5-ALA hydrochloride product, Gleolan, has a U.S. indication that helps explain why the product name matters. Surgeons use it to make malignant tissue easier to see during certain glioma operations. Its label covers this imaging use. [2] [13]

Questions to take to your clinician

If tiredness is why you are considering 5-ALA with iron, start with what might be causing it. Would a blood count or iron studies help? If you already take iron, how much elemental iron would the proposed product add? Extra iron can cause stomach upset and can interfere with medicines such as levothyroxine. People with hereditary hemochromatosis can accumulate too much iron. [3]

Ask what the trial measured in people whose situation resembles yours. In the Oxford TALEN trial, for example, researchers recorded enrollment of 48 cardiac surgery patients in a dose-finding study of the combination. Its ClinicalTrials.gov record lists the study as completed and has no posted results. For a question about day-to-day fatigue, the eight-week fatigue study offers a more relevant comparison. [14] [1]

Questions people ask

Does 5-ALA with iron help everyday fatigue?

One eight-week study in 70 otherwise healthy adults found a greater reduction in self-rated fatigue when researchers added 5-ALA to an iron-containing tablet. People in the 5-ALA group started with higher fatigue scores. How long the improvement lasts is unclear.

What did the post-COVID study find?

A four-week randomized study in 42 people with fatigue after COVID-19 found no statistically significant difference in fatigue change between the groups. Safety was the main outcome. The small sample leaves uncertainty about benefits and harms.

Does it lower blood sugar?

In a 12-week trial in adults with mildly elevated glucose, the highest-dose combination improved fasting and two-hour glucose readings compared with placebo. Two trials in type 2 diabetes reported different results. In one, average HbA1c fell most in the higher-dose group. In the other, people already taking diabetes medication had the same average HbA1c change with the combination as with placebo.

What should I ask before taking a product with iron?

Ask what could be causing your fatigue, whether iron testing would help, how much elemental iron the product contains and whether it could interfere with your medicines. Iron overload conditions such as hereditary hemochromatosis make extra iron a particular concern.

The evidence

These links lead to the original studies, registry records and product information discussed above. You can also browse the Science research library.

Fatigue trial 1. Reduction of fatigue and anger-hostility by the oral administration of 5-aminolevulinic acid phosphate: a randomized, double-blind, placebo-controlled, parallel study. Sci Rep (2020). PubMed 32994490
Official label 2. Gleolan (aminolevulinic acid hydrochloride) prescribing information. U.S. prescribing information (2026). Product label
Iron guidance 3. Iron fact sheet for health professionals. NIH Office of Dietary Supplements. Source
Exercise trial 4. Impact of 5-aminolevulinic acid with iron supplementation on exercise efficiency and home-based walking training achievement in older women. J Appl Physiol (1985) (2016). PubMed 26514619
Exercise trial 5. The Impact of 5-Aminolevulinic Acid Supplementation on Redox Balance and Aerobic Capacity. Int J Mol Sci (2024). PubMed 38256062
Sarcopenia trial 6. Efficacy and Safety of 5-Aminolevulinic Acid Combined with Iron on Skeletal Muscle Mass Index and Physical Performance of Patients with Sarcopenia: A Multicenter, Double-Blinded, Randomized-Controlled Trial (ALADDIN Study). Nutrients (2023). PubMed 37447194
Mouse study 7. Sodium ferrous citrate and 5-aminolevulinic acid improve type 2 diabetes by maintaining muscle and mitochondrial health. Obesity (Silver Spring) (2023). PubMed 36823345
Glucose trial 8. 5-aminolevulinic acid, a precursor of heme, reduces both fasting and postprandial glucose levels in mildly hyperglycemic subjects. Nutrition (2013). PubMed 23759263
Registry results 9. 24-week randomized study of 5-aminolevulinic acid with sodium ferrous citrate in adults with type 2 diabetes. EU Clinical Trials Register (results posted 2021). EudraCT 2017-004959-23
Acute COVID-19 trial 10. Safety and efficacy of 5-aminolevulinic acid phosphate/iron in mild-to-moderate coronavirus disease 2019: A randomized exploratory phase II trial. Medicine (Baltimore) (2023). PubMed 37653769
Post-COVID trial 11. Imamura, Sugihara and Hirahata. Study report on fatigue after COVID-19 (jRCTs031210123). ALA-Porphyrin Science, volume 10, pages 15 to 22. Original report (PDF) Registry results
Leigh syndrome trial 12. A phase III double-blind, placebo-controlled, randomized withdrawal trial of 5‑aminolevulinic acid hydrochloride with sodium ferrous citrate for efficacy and safety in patients diagnosed as Leigh syndrome. PLoS One (2026). PubMed 42467686
Developer statement 13. SPP-004 clinical development update. SBI Pharmaceuticals and Saitama Medical University (July 21, 2026). Source
Trial registration 14. Pre-operative 5-Aminolevulinic Acid to Activate Haem Oxygenase to Improve Outcomes in Cardiac Surgery: A Dose Finding Study. ClinicalTrials.gov, TALEN. NCT07027670
Registry results 15. 24-week randomized study of two doses of 5-aminolevulinic acid with sodium ferrous citrate in adults with type 2 diabetes. EU Clinical Trials Register (results posted 2021). EudraCT 2017-004944-39

This article is for education. Any treatment decision should be made with a qualified physician. Individual results vary.